主会场

嘉宾简介

姓名        :

徐仁和

报告题目 :

职称        :

教授

个人简介 :

日本东京大学博士。先后在以色列Bar-Ilan大学和美国NIH从事博士后研究,然后在威斯康星大学WiCell研究中心任高级研究员,师从人胚干细胞之父James Thomson教授。他于2005年受聘为康涅狄克大学遗传与生物发育系副教授,康涅狄克大学干细胞技术中心主任。2014年被聘为澳门大学健康科学学院教授。徐教授长期从事干细胞研究和应用,主持多项研究课题,获基金逾千万美元。他最先发现可维持人胚干(ES)细胞的自我更新和长期培养的因子,而无需动物滋养细胞;揭示人诱导性多能干(iPS)细胞常见基因拷贝数变化;并用人胚干细胞经滋养层细胞分化的间充质干细胞(TMSC, patented)治疗多发性硬化症等自身免疫性动物模型取得显著疗效。在Nature子刊,Cell子刊和PNAS等生物医学主流期刊发表论文,综述和著作近60篇,获引用近5000次(h指数28)。其科研成果多次被世界主流媒体如Science,Reuters,和USA Today等报道。徐教授还获得多项发明专利并得到商业化应用,并于2012年在美国创建ImStemBiotechnology公司。他被授予1997年度美国国立癌症研究所Frederick(NCI-Frederick)杰出科学进步奖,2007年度康涅狄克科研协会干细胞研究特殊贡献奖,2007年度康涅狄克州政府蓝皮书荣誉证书,和2009年度伊朗罗彦研究所国际科研奖。

个人履历 :

Ph.D. University of Tokyo, Tokyo, Japan

M.S. Central South University (formerly Xiangya Medical University), Changsha, China

B.M. South China University (formerly Hengyang Medical College), Hengyang, China

2014 - present Professor, Faculty of Health Sciences, University of Macau, Macau

2006 - 2014 Associate Professor, Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT, USA

1999 - 2006 Senior Scientist, WiCell Research Institute, Madison, WI, USA

1994 - 1996 Research Fellow, NCI-FCRDC, NIH, Frederick, MD, USA

科研成果 :

In early 2000s, we first reported that BMP4 induces human embryonic stem cell (hESC) differentiation into trophoblast, and that a BMP inhibitor and high-dose FGF2 are sufficient to sustain self-renewal and prolonged culture of hESC, which got rid of animal feeder cells. In 2008, we identified TGFb signaling regulates pluripotency via direct binding of SMADs to the promoter of NANOG. In 2011, we were among the first to reveal recurrent copy number variations in human induced pluripotent stem cells. Since 2014, we started to use hESC-differentiated mesenchymal stem cells (MSC) to treat multiple sclerosis and colitis in animal models, and found a novel and efficient way to derive MSC from hESC via an intermediate trophoblast step (TMSC, patented). TMSC are being developed as a potential investigational new drug under the evaluation of Food and Drug Administration in U.S. Recently, we found that spheroidal formation allows hESC and MSC to be stored under ambient conditions for over 4 and 7 days, respectively, without loss of their viability and biological functions. This new method, termed spheropreservation, remarkably facilitates long-distance cell transportation by avoiding the tedious and costly cryopreservation procedures.

Current research interests in Xu lab include:

1、 Therapeutic application of TMSC in inflammatory diseases and injuries;

2、 Immunogenicity and biosafety of hESC-derived allografts;

3、 Study of eye development and disease using hESC-based models

.